TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of squamous cell carcinoma of esophagus. Preoperative stage Ⅱ-Ⅲ by endoscopic ultrasound, CT of the chest and abdomen,and esophagogram.~* Age ranges from 18 to 70 years.~* Patients must not have received any prior anticancer therapy.~* Performance status of 0 to 1~* Estimated life expectancy of at least 6 months.~* Tumor can be measured according to RECIST criteria~* Signed informed consent document on file.~* Females with childbearing potential must have a negative serum pregnancy~* Adequate organ function including the following:~Bone marrow: Absolute neutrophil count (ANC) greater than or equal 1.5×109/L Platelets greater than or equal 80×109/L Haemoglobin greater than or equal 80g/L Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN), Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 times ULN Renal: calculated creatinine clearance rate≥60ml/min. test within 7 days prior to study enrollment.~Exclusion Criteria:~* Carcinoma at the upper part of esophagus~* Histologic diagnosis of adenocarcinoma of esophagus.~* Prior treatment for esophageal cancer.~* Active infection.~* Pregnant or breast feeding.~* History of significant neurological or mental disorder, including seizures or dementia.~* Prior invasive malignancy in 5 years (except for carcinoma in situ).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- nab-paclitaxel plus cisplatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Addressing Health Disparities in Childhood Obesity, One Summer at a Time

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children who are enrolled in one of the 4 high-risk schools in 2nd through 5th grade, whose parents/legal guardians provide consent and provide assent.~Exclusion Criteria:~* Children who are not enrolled in the selected schools, or whose parents/legal guardians do not provide consent, or whom do not provide assent.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 13 Years
- Healthy Volunteers: t

Study Arms:
- Immediate intervention (Type: EXPERIMENTAL): Summer activity program: Children will receive the summer scorecard program during the first summer of the 2-year study.
- Delayed intervention (Type: EXPERIMENTAL): Summer activity program: Children will receive the summer scorecard program during the second summer of the 2-year study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Single, Multiple Dose and Food Effect Study of SHR2285 Tablets on Pharmacokinetics and Pharmacodynamics in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy subjects, aged 18-55 (including boundary);~2. Body mass index (BMI) between 18 to 28 kg/m2 (including boundary), male body weight ≥50 kg and \<90 kg , female body weight ≥45kg and \<90kg;~3. Participant with no clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters.~4. Understand the study procedures and methods, voluntary to participate in the study and signed the informed consent.~Exclusion Criteria:~1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin \> upper limit of normal (ULN) during screening/baseline.~2. Serum creatinine\> ULN during screening/baseline.~3. Positive faecal occult blood~4. Abnormal coagulation function.~5. A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.~6. Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening.~7. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration.~8. Human immunodeficiency virus antibody, syphilis serological examination, hepatitis b virus surface antigen, hepatitis c virus antibody were positive.~9.3 months prior to screening involved in any drug or medical device clinical studies or within 5 half-life of drugs before screening.~10.Female subjects who did not receive contraception at least 30 days before administration and etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SHR2285 Part 1A (Type: EXPERIMENTAL): Participant received one of 7 dose levels of SHR2285 tablet as single-dose oral administration
- Placebo Part 1A (Type: PLACEBO_COMPARATOR): Single ascending doses of placebo orally
- SHR2285 Part 1B (Type: EXPERIMENTAL): Participant received one dose of SHR2285 tablet as single-dose oral administration
- Placebo Part 1B (Type: PLACEBO_COMPARATOR): Single doses of placebo orally
- SHR2285 Part 2 (Type: EXPERIMENTAL): Participant received one of 4 dose levels of SHR2285 tablet as multi-dose oral administration
- Placebo Part 2 (Type: PLACEBO_COMPARATOR): Multiple ascending doses of placebo orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of severe hypertension~Exclusion Criteria:~* Diastolic blood pressure (DBP) \< 60 mm Hg~* Serum potassium \< 3.5 or \> 5.5 mEq/L in the absence of all potassium supplements~* Refractory hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or DBP ≥ 110 mmHg and unresponsive to triple-drug regimens~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients must meet Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD)~* patients must achieve a score of 80 or more on the Full Scale Intelligence Quotient~* child or adolescent patients must be 10 to 16 years old~* must be able to communicate in English~* must be able to swallow capsules~* be reliable to keep appointments for clinic visits and all related tests~Exclusion Criteria:~* patients who weigh less than 25 Kg or greater than 70 Kg~* patients with a history of alcohol or drug abuse on a repeated basis within the past 3 months~* patients with documented history of autism, Asperger's syndrome or pervasive developmental disorder~* females who are pregnant or breastfeeding~* patients with a history of severe allergy to more than one class of medications~* patients with documented history of bipolar I or bipolar II disorder, or psychosis

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): Atomoxetine will be administered at 1.0 to 1.4 milligram/kilogram/day (mg/kg/day) given orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be packaged in the same way as experimental drug to enforce double-blind study design. Placebo will be administered orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients 18 years of age or older~* Patients that are being prescribed REVLIMID in combination with dexamethasone for the treatment of multiple myeloma and that have received at least one prior therapy~* Patient must be willing and able to provide informed consent~* Patients will be informed about the Registry and will have to sign a specific Registry Informed Consent Form~* Be able to ask questions prior to signing the Subject Information and Consent Form~* Be clearly informed that their involvement/participation in the registry is voluntary~* Understand that their medical care will not be altered in any way by their participation in the registry~Exclusion Criteria:~- A Patient who is unwilling or unable to provide informed consent will not be included.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REVLIMID (Type: None): Taiwanese patients treated with REVLIMID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma of the pancreatic head or body~* Patients must have radiographically-confirmed surgically resectable or borderline resectable disease at study entry staged at T1-3, NO-1 and MO~* Age \>/= 18years~* Life expectancy of greater than 6 months in the opinion of the investigator, excluding theh pancreatic cancer~* Eastern Cooperative Oncology Group (ECOG) performance status \</= 1~* Required laboratory data (see protocol)~* Disease assessment by CT scan within 4 weeks of study entry~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Patients may not be receiving any other investigational agent~* Patients with metastatic disease are excluded from this clinical trial~* History of allergic reactions attributed to Fluorouracil (5FU), oxaliplatin and gemcitabine~* No prior chemotherapy or radiation therapy for pancreatic cancer (previous chemotherapy or radiation therapy for other malignancies is permitted)~* Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study.~* Uncontrolled serious intercurrent illness including, but not limited to, ongoing or serious active infection requiring IV antibiotics for over 30 days, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic, stable atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant or breastfeeding women are excluded from this study.~* Known HIV-positive patients are ineligible~* Patients with unresectable disease are excluded form the protocol (see Appendix B for National Comprehensive cancer Network \[NCCN\] criteria for determining resectability status). Surgical resectability must be confirmed by a surgeon experienced in pancreatic surgery.~* Patients with pancreatic tail lesions will be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant Chemo-Radiotherapy and Resection (Type: EXPERIMENTAL): 2 cycles - FOLFOX6 (1 month) Gemcitabine/RT (5-6 weeks) Rest period 2 weeks Re-staging evaluation (CT scan to be done during the 2 weeks of rest) Surgery (To be performed no later than 6 weeks after completion of chemo-radiation)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* self-declared white/Caucasian~* self-declared African-American~* active~* ambulatory~* no evidence of medical disease~Exclusion Criteria:~* alcohol use of 3 or more drinks per day~* HIV or hepatitis (B or C) infection~* isoniazid~* disulfiram~* phenobarbital~* phenytoin~* carbamazepine~* rifampicin~* valproic acid~* probenecid~* St. John's Wort

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- White subjects (Type: EXPERIMENTAL): 2 x 500 mg acetaminophen by mouth once
- Black subjects (Type: EXPERIMENTAL): 2 x 500 mg acetaminophen by mouth once

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and Women ≥ 18 years of age~* Diagnosed with stage IV Non-Small Cell Lung Cancer~* Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options.~Exclusion Criteria:~* Subjects with untreated CNS metastases are excluded.~* Subjects with carcinomatous meningitis~* Subjects with an active, known or suspected autoimmune disease.~* Subjects with a condition requiring systemic treatment with either corticosteroids ( \> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment.~* Women who are pregnant, plan to become pregnant, and/or breastfeed during the study.~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab+Ipilimumab (Type: EXPERIMENTAL): Part 1~Specified Dose on Specified Days
- Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy (Type: EXPERIMENTAL): Part 2~Specified Dose on Specified Days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with a stable dose of one of the following for at least 3 months prior to screening: \* \>=1000 mg/day immediate-release metformin; or metformin \>=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy.~* HbA1c between 7.1% and 11.0%, inclusive.~* Body Mass Index (BMI) \>21 kg/m\^2 and \<35 kg/m\^2.~Exclusion Criteria:~* Have participated in this study previously, or any other study using exenatide or GLP-1 analogs.~* Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening.~* Have characteristics contraindicating metformin or sulfonylurea use.~* Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening.~* Have used drugs for weight loss within 1 month of screening.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Placebo lead-in; exenatide 5 mcg for 4 weeks; exenatide 10 mcg for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in volume equal to exenatide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for Liver Recipients:~* Received liver from living parent donor~* Received transplant at least 4 years prior to study entry~* Less than 18 years of age at time of transplant~* Parent or guardian willing to provide informed consent~Inclusion Criteria for Liver Donors:~* Willing to participate in this study~Exclusion Criteria for Liver Recipients:~* Underwent transplant because of liver failure related to autoimmune disease~* Underwent transplant of a second organ simultaneously with or after liver transplant OR liver retransplantation~* Receiving immunosuppression with more than one drug~* 50% increase in dose of current immunosuppressive drug~* HIV infection~* Hepatitis B or C virus infection~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Immunosuppression Withdrawal (Type: EXPERIMENTAL): Recipients of parental living donor liver transplants 4 or more years prior to trial enrollment, who also had stable allograft function during the preceding 6 months while taking a single immunosuppressive drug were permitted to undergo withdrawal of immunosuppression therapy. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.~Participants are carefully evaluated/monitored throughout the study by assessments including but not limited to liver biopsy, liver tests and clinic visits, alloantibodies, autoantibodies and quantitative immunoglobulin G test results.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) of up to 40 kg/m2~* Roux-en-Y gastric bypass (RYGB) surgery performed ≥12 months prior~* Diagnosis of PBH~* At least 2 episodes during screening 2-week run-in phase of severe hypoglycemia~Exclusion Criteria:~* Other cause of endogenous hyperinsulinism other than PBH~* Metabolic or bariatric surgical procedure other than RYGB~* History of non-RYGB upper GI surgery~* Use of agents that may interfere with glucose metabolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: EXPERIMENTAL): patients will receive two dose regimens of exendin 9-39 and one placebo
- Treatment Group 2 (Type: EXPERIMENTAL): patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete